Alterity therapeutics presents positive data from ath434 phase 2 trial at the 2025 international congress of parkinson's disease and movement disorders

– data demonstrate ath434 slows disease progression and stabilizes orthostatic hypotension – – new analysis increases overall confidence in the phase 2 trial results – – state-of-the-art neuroimaging and biomarker analysis advance understanding of msa diagnosis – melbourne, australia and san francisco, oct. 09, 2025 (globe newswire) -- alterity therapeutics (asx: ath, nasdaq: athe) (“alterity” or “the company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced  that data from the ath434-201 randomized, double-blind phase 2 clinical trial in multiple system atrophy (msa) was featured at the 2025 international congress of parkinson's disease and movement disorders (mds) that took place in honolulu, hi, usa. “the aggregate data from our double-blind trial continue to demonstrate the potential of ath434 as a disease modifying therapy for msa,” said david stamler, m.d.
MSA Ratings Summary
MSA Quant Ranking